PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close
MOA Life Plus is attempting to diversify into AI data center and fintech businesses while its health-supplement and cosmetics revenue has shrunk for four straight years amid recurring net losses.
2025 revenue of roughly KRW 11.2bn shrank sharply from about KRW 100.4bn in 2022, with the operating margin widening to -58.2%
Q2 2026 net loss attributable to owners surged again to roughly KRW -7.9bn, with non-operating swings driving results
The entire stake (about 17%) held by controlling shareholder MOA Data is pledged as collateral to Sangsangin Savings Bank, posing governance risk
The company is simultaneously pursuing new businesses including its first paid AI data center contract, a video AI platform partnership, and a fintech stake acquisition (Seed Financial)
An extraordinary general meeting is scheduled for September 30, 2026 — agenda items on new business purposes and board matters should be checked
Founded in 1999, MOA Life Plus grew on the back of its poly-gamma-glutamic acid (PGA) biotechnology platform and listed on KOSDAQ in 2016.
The company still holds a drug pipeline, including a cervical dysplasia treatment under Phase 2/3 clinical approval and a Duchenne muscular dystrophy/sarcopenia treatment technology licensed to PMGC Holdings that is preparing for Phase 2 trials.
More recently, however, the company has shifted its center of gravity toward becoming a bio-consumer goods firm, building a vertically integrated structure from raw materials to finished products and generating tangible sales mainly through health supplements and functional cosmetics manufacturing and distribution.
Centered on its flagship brand Doctors PGA, the company has expanded overseas distribution by listing on Japan's DHOLIC Commerce, Rakuten, Qoo10, and Yahoo Japan Shopping, alongside domestic online, offline, and duty-free channels.
It has also been targeting the cosmeceutical market by supplying PGA raw materials to global cosmetics companies.
In parallel, the company signed its first paying-customer contract for its AI data center business and is pursuing a real-footage-based video AI platform venture with Stone V Studio, led by film director Han Han-min, extending into data and AI.
It also acquired a stake in Seed Financial, an electronic and prepaid payment platform company, to build a fintech business foundation. The current controlling shareholder, MOA Data, holds roughly a 17% stake, all of which has been pledged as collateral to a financial institution.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩2.3B | -₩1.2B | −50.9% |
| 2025Q3 | ₩1.2B | -₩1.5B | −124.4% |
| 2025Q4 | ₩4.6B | -₩2.8B | −60.7% |
| 2026Q1 | ₩2.3B | -₩1.4B | −58.2% |
| 2026Q2 | ₩2.3B | -₩1.2B | −52.8% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩100.4B | -₩14.6B | -₩23.1B | −14.6% | −106.7% | 120.5% |
| 2023 | ₩18.2B | -₩5.2B | ₩8.1B | −28.3% | 24.5% | 37.1% |
| 2024 | ₩15.6B | -₩5.5B | -₩7B | −35.4% | −18.7% | 53.7% |
| 2025 | ₩11.2B | -₩6.5B | -₩13.1B | −58.2% | −42.7% | 39.4% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
2025 revenue came to roughly KRW 11.2bn, down for a fourth straight year from about KRW 15.6bn in 2024, KRW 18.2bn in 2023, and KRW 100.4bn in 2022.
The operating loss narrowed from about KRW 14.6bn in 2022 to KRW 5.2bn in 2023 and KRW 5.5bn in 2024, before widening again to about KRW 6.5bn in 2025; the operating margin moved from -14.6% (2022) to -28.3% (2023), -35.4% (2024), and -58.2% (2025), deteriorating as fixed costs outpaced the revenue decline.
Net income attributable to owners flipped from a loss of about KRW 23.1bn in 2022 to a profit of about KRW 8.1bn in 2023 even as the operating loss persisted, a result likely driven by a one-off non-operating item; the net loss then widened again to about KRW 7.0bn in 2024 and KRW 13.1bn in 2025.
On a quarterly basis, the owner net loss reached about KRW 7.0bn in Q2 2025, narrowed sharply to about KRW 0.7bn in Q3, and widened again to about KRW 3.9bn in the seasonally stronger Q4 (revenue of about KRW 4.6bn).
Q1 2026 was comparatively stable with revenue of about KRW 2.3bn and a net loss of about KRW 1.1bn, but in Q2 2026, while revenue held at a similar KRW 2.3bn level, the net loss surged again to about KRW 7.9bn.
This pattern of large quarterly net-loss swings largely independent of revenue size suggests non-operating items, rather than core operations, are the dominant driver of bottom-line results.
Consolidated total equity fell sharply from about KRW 67.3bn in 2022 to KRW 35.8bn in 2023 (likely reflecting a reduction in non-controlling interests), rose to about KRW 40.5bn in 2024, then declined again to about KRW 30.6bn in 2025; the debt ratio dropped from 120.5% in 2022 to 37.1% in 2023 and has since been managed at 53.7% (2024) and 39.4% (2025).
Operating cash flow was positive only in 2023 at about KRW 6.2bn, with outflows of about KRW 20.6bn in 2022, KRW 0.5bn in 2024, and KRW 6.0bn in 2025.
South Korea's health-supplement and functional cosmetics markets are maturing with intensifying competition, while the cosmeceutical space—bridging cosmetics and pharmaceuticals—is drawing attention as a newer growth area.
MOA Life Plus holds some competitive edge through its differentiated PGA bio-material, allowing it to pursue both ingredient supply and finished-product sales simultaneously, but it still competes against numerous domestic and overseas bio-material and cosmetics companies.
Overseas e-commerce channels, including in Japan, offer growth potential on the back of K-beauty demand, though competition among local platforms and brands remains intense.
The company has been selected for a government-supported joint technology development project on osteoporosis-related functional efficacy, building a foundation for individually recognized ingredient registration.
Meanwhile, the AI data center and fintech businesses are entering markets already dominated by major hyperscalers and established payment gateway operators respectively; the company's positioning is in relatively niche applications such as "physical AI"/healthcare-data-specialized infrastructure and payments linked to beauty and healthcare platforms.
These new ventures remain at an early commercialization stage, with limited disclosed metrics to gauge revenue contribution or growth pace.
As a result, the company occupies a complex industry position, simultaneously operating a maturing, competitive bio-consumer goods business and unproven, early-stage AI and fintech ventures.
The company has stated that 2026 will focus on stabilizing its supplement- and cosmetics-centered core business and expanding distribution channels, while building a structure connecting domestic online/offline, duty-free, and overseas distribution, and gradually incorporating AI-based new businesses. In February 2026, it signed its first paying-customer contract for its "physical AI data center,
The current share price trades at a level below the company's disclosed book value per share, placing it in a discount-to-net-asset range.
However, with the net loss attributable to owners persisting through the trailing four quarters (Q3 2025 through Q2 2026), earnings-based valuation metrics remain difficult to compute meaningfully. The company has not paid dividends in recent years, limiting dividend-based comparisons as well.
Given that the brief return to net profit in 2023 was followed by a return to net losses, it appears premature to assess any earnings recovery until the revenue contribution from new businesses (AI data center, fintech) is confirmed through actual disclosures.
It is also worth noting that the price-to-book ratio has formed within a valuation pattern typical of small-cap bio/consumer names that have faced concerns over shrinking core operations and equity erosion.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
The company is simultaneously pursuing three distinct new business tracks: its first paid AI data center contract, a video AI platform collaboration, and a fintech stake acquisition. If successfully established, these could become new revenue sources complementing existing health-supplement and cosmetics sales.
However, all three remain at an early stage, and their revenue contribution has not yet been confirmed through disclosures.
The debt ratio fell sharply from 120.5% in 2022 to 37.1% in 2023 and has since remained at a relatively manageable 53.7% (2024) and 39.4% (2025). This suggests reduced financial leverage burden compared to the past. However, total equity itself has been declining again since 2024, warranting continued monitoring.
The company possesses a differentiated bio-material, poly-gamma-glutamic acid (PGA), and has stated it is proving its ingredient business competitiveness by supplying it to global cosmetics companies. Plans to target the cosmeceutical market and expand into Europe are also being pursued.
Its vertically integrated raw-material-to-finished-product structure could be a strength in cost and quality control.
Revenue has declined for four consecutive years, from about KRW 100.4bn in 2022 to about KRW 11.2bn in 2025. The operating margin has also worsened from -14.6% to -58.2%, with fixed-cost burden continuing to overwhelm a shrinking top line.
Should the core business's revenue decline persist before new ventures gain traction, profitability recovery could be further delayed.
In both Q2 2025 and Q2 2026, the net loss attributable to owners expanded sharply to roughly KRW -7.0bn to -7.9bn regardless of revenue size. This indicates non-operating items outweigh core operating results, reducing earnings predictability. If this volatility recurs, the risk of accelerated equity erosion cannot be ruled out.
The entire stake (roughly 17%) held by controlling shareholder MOA Data is pledged as collateral to Sangsangin Savings Bank, and disclosures state that a full execution of the collateral could trigger a change in the controlling shareholder.
The collateral contract periods have been amended and extended multiple times, with maturities repeatedly approaching. Continued governance uncertainty could affect the consistency of management strategy.
The entire stake held by controlling shareholder MOA Data is pledged as collateral to Sangsangin Savings Bank, and if a debt-related acceleration event occurs, execution of the collateral could change the controlling shareholder. The collateral contracts have been amended and extended multiple times through 2026.
A change in controlling shareholder could bring changes to management strategy continuity or the direction of new business initiatives.
The company is simultaneously pursuing bio-consumer goods, AI data centers, video AI, and fintech businesses of very different natures. Each venture is at an early contracting stage, and actual revenue scale and profitability have not yet been verified through disclosures.
Operating multiple new businesses at once carries the risk of resource allocation and organizational capacity being spread thin.
Operating losses have persisted for multiple years, with the operating margin worsening to -58.2% in 2025. Consolidated total equity has also been trending down again since 2024.
If losses persist over the long term, the possibility of equity dilution from further capital raising (rights issues, convertible bonds, etc.) cannot be ruled out.
Extraordinary general meeting is held — the agenda items on new business purposes and director appointments, and the resolution outcomes, should be checked.
Q3 2026 results disclosure — check whether new businesses (AI data center, fintech) begin contributing to revenue and whether net-loss volatility persists.
Monitor for additional disclosures on the renewal, maturity, or execution of the collateral contracts tied to MOA Data's pledged stake.
Check whether the expansion of Japanese e-commerce channels (DHOLIC Commerce, Rakuten, Qoo10, Yahoo Japan) and cosmeceutical ingredient supply actually contributes to revenue.
MOA Life Plus is attempting a structural business transformation, simultaneously pursuing distinctly different new ventures—AI data centers, video AI, and fintech—while its existing health-supplement and cosmetics revenue has shrunk for four consecutive years and its operating loss margin has widened.
Apart from a brief return to net profit in 2023, the company has recorded net losses attributable to owners in most periods, and a pattern of sharply widening net losses regardless of revenue size repeated in both Q2 2025 and Q2 2026, leaving earnings predictability relatively low.
On the balance sheet, the debt ratio improved markedly from 120.5% in 2022 to 39.4% in 2025, though total equity has trended down again since 2024.
A governance risk also exists in that the entire stake held by controlling shareholder MOA Data is pledged to a financial institution, meaning a change in controlling shareholder could occur if the collateral is executed.
All of the new business ventures remain at an early contracting or commercialization stage, and their actual revenue contribution will need to be confirmed through future quarterly disclosures.
The extraordinary general meeting on September 30, 2026, and the upcoming Q3 results disclosure are likely to be key junctures for assessing the company's future business direction and earnings trajectory.
Report written 2026-09-12 · Data as of 2026-09-11
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.